Product Information
CARBIDOPA-LEVO ER 50-200 TAB is a generic product labeled by Amneal Pharmaceuticals NY LLC, priced at $0.1796 per EA under NDC 60219203401. Its NADAC has been published 161 times since Sep 6, 2023.
FDA first approved this application on May 14, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50; 200 mg/1; mg/1
Manufacturer
Amneal Pharmaceuticals NY LLCNDC
60219203401
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA076521FDA Approved
5/14/2004
TE Code
AB
On Market Since
12/21/2022
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVO ER 50-200 TAB has been published 161 times since Sep 6, 2023, and over the history we have for it it has declined 29.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1796 per EA |
|---|---|
| All-time high | $0.2606 (Nov 15, 2023) |
| All-time low | $0.1551 (May 22, 2024) |
| 52-week high | $0.2057 |
| 52-week low | $0.1676 |
| Median price | $0.1996 |
| Average price | $0.2030 |
| Largest weekly change | +52.4% (Jun 19, 2024) |
| Weeks tracked | 161 |
| Tracking since | Sep 6, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CARBIDOPA and LEVODOPA market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amneal Pharmaceuticals NY LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CARBIDOPA and LEVODOPA market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVO ER 50-200 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVO ER 50-200 TAB, manufactured by Amneal Pharmaceuticals NY LLC, is $0.1796 per EA (NDC 60219203401), effective Sep 30, 2026.
How has the price of CARBIDOPA-LEVO ER 50-200 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVO ER 50-200 TAB has declined 29.5%. It has been tracked across 161 weekly CMS publications since Sep 6, 2023.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVO ER 50-200 TAB?
Since Sep 6, 2023, the NADAC for CARBIDOPA-LEVO ER 50-200 TAB has ranged from a low of $0.1551 (May 22, 2024) to a high of $0.2606 (Nov 15, 2023), with a median of $0.1996 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVO ER 50-200 TAB?
No other NADAC-published product currently shares the active ingredient and strength of CARBIDOPA-LEVO ER 50-200 TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CARBIDOPA-LEVO ER 50-200 TAB?
CARBIDOPA-LEVO ER 50-200 TAB (NDC 60219203401) is labeled by Amneal Pharmaceuticals NY LLC, and CMS classifies it as a generic product.